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Until now, the refusal by many researchers to recognize curative 
treatments for pelvic pain other than the individual symptom-
atic treatment protocol is very disappointing. Furthermore, it 
should be recognized that finding an optimal individual treat-
ment protocol may require a period of trial and error. This re-
fusal appears to have shocked people suffering from chronic pain 
all over the world and those pursuing the best approach and cure 
through primary resolution of the cause of the pain. In a review 
article in the March issue, Yang et al. [1] stress the primacy of 
the host defense mechanisms and assert that the dysregulation 
of innate immune response can lead to inflammatory disease 
pathogenesis. They also suggest new challenges for the develop-
ment of novel targets and appropriate situation-dependent ad-
justments for the treatment of auto-inflammatory disorders in-
cluding interstitial cystitis (IC). Urogenital chronic pain includ-
ing prostate or bladder pain is a significant healthcare issue and 
is not etiology specific one. I want readers to focus on the 2 
prominent clinical conditions in practice, which are chronic 
prostatitis/chronic pelvic pain syndrome and IC/painful blad-
der syndrome. There is a new turnaround on the urologist’s 
stance over the symptomatic treatment of urologic inflammato-
ry disease, with pursuance of the primary causes of the diseases 
and with priorities placed on auto-inflammation. Urologists 
must recognize recent advances in the regulatory mechanisms 
of host defense and various inflammatory diseases to optimize 
diagnostic and therapeutic strategies for the difficult-to-manage 
chronic pain that does not routinely respond to traditional treat-
ment. Inflammasomes are multiprotein complexes responsible 
for the activation of caspase-1 and caspase-5 protease required 
for processing and activation of the proinflammatory cytokines 
interleukin (IL)-1β and IL-18 [2]. Moreover, NLRP3 (nucleo-
tide binding oligomerization domain [NOD/NACHT], LRR, 
and PYD domains containing protein 3; also known as NALP3, 
cryopyrin, or CIAS1) expression is found in the urothelial layer 
in the bladder [3]. I think that the presence of NALP3 in epi-
thelial cells lining the urogenital tracts allows the rapid sensing 
of invading pathogens, thereby triggering an innate immune 
response.
REFERENCES
1. Yang CS, Shin DM, Jo EK. The role of NLR-related protein 3 inflam-
masome in host defense and inflammatory diseases. Int Neurourol J 
2012;16:2-12.
2. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular 
platform triggering activation of inflammatory caspases and pro-
cessing of proIL-beta. Mol Cell 2002;10:417-26.
3. Kummer JA, Broekhuizen R, Everett H, Agostini L, Kuijk L, Marti-
non F, et al. Inflammasome components NALP 1 and 3 show dis-
tinct but separate expression profiles in human tissues suggesting a 
site-specific role in the inflammatory response. J Histochem Cyto-
chem 2007;55:443-52.
Editorial
http://dx.doi.org/10.5213/inj.2012.16.1.1
pISSN 2093-4777 · eISSN 2093-6931